phase_dancer
Bluelight Crew
- Joined
- Mar 12, 2001
- Messages
- 6,179
Additionally a new paragraph (c) is inserted in section 4 to capture in the
definition of dangerous drug a chemical that is an analogue of a dangerous
drug. This means that a drug with a chemical structure which is substantially similar to the chemical structure of a scheduled drug and which has a substantially similar pharmacological effect is a dangerous drug for the purpose of the Act.
If the term 'substantially similar pharmacological effect' is to be as broadly interpreted as it is with chemical structure, then even metabolism could be included. On that basis, chemicals could also be included that don't even cause pronounced psychotropic effects, but have similar effects on BP, heart rate etc and which may be metabolised by the same enzymes. What would that mean for OTC products containing xanthines, and other presently acceptable compounds?